Bagsværd, Denmark, 15 August 2022 – On 3 August 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme in
Three Motley Fool contributors have identified stocks to buy and hold forever. Here's why they chose Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX). David Jagielski (Eli Lilly): If you're planning to hold a stock forever, then you need to be comfortable with its growth potential.
Prothena (PRTA) incurs a loss in the second quarter while revenues miss estimates.